Narayanan Developing Treatments For Alphaviruses
Aarthi Narayanan, Professor, Biology, received funding for the project: "Further the development of Omaveloxolone and Bardoxolone methyl as broadly effective countermeasures against alphaviruses to Support the Battelle Accelerated Therapeutics for Combating Acute Viral Epidemics Program."
The principal purpose of this program is to conduct Research and Development into medical, pharmaceutical, and diagnostic technologies to enhance mission effectiveness of military personnel, collaborating with industry partners for the advanced development of medical countermeasures for chemical and biological defense.
For her part, Narayanan will further the development of Omaveloxolone and Bardoxolone methyl as broadly effective countermeasures against alphaviruses.
Narayanan received up to $1,000,000 from Battelle Memorial Institute on a subaward from Defense Threat Reduction Agency through the Medical CBRN Defense Consortium. This funding began in Nov. 2023 and will end in late Dec. 2025.
###
ABOUT GEORGE MASON UNIVERSITY
George Mason University is Virginia’s largest public research university. Located near Washington, D.C., Mason enrolls more than 40,000 students from 130 countries and all 50 states. Mason has grown rapidly over the past half-century and is recognized for its innovation and entrepreneurship, remarkable diversity, and commitment to accessibility. In 2023, the university launched Mason Now: Power the Possible, a one-billion-dollar comprehensive campaign to support student success, research, innovation, community, and stewardship. Learn more at gmu.edu .